Compare SLGL & BPRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLGL | BPRN |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.1M | 238.5M |
| IPO Year | 2016 | 2022 |
| Metric | SLGL | BPRN |
|---|---|---|
| Price | $75.40 | $34.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | ★ 25.0K | 4.5K |
| Earning Date | 05-22-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.93% |
| EPS Growth | N/A | ★ 74.84 |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.96 |
| Revenue Next Year | $223.84 | $6.13 |
| P/E Ratio | ★ N/A | $38.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.80 | $29.21 |
| 52 Week High | $97.97 | $37.99 |
| Indicator | SLGL | BPRN |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 48.90 |
| Support Level | $66.48 | $34.66 |
| Resistance Level | $81.64 | $36.53 |
| Average True Range (ATR) | 6.76 | 0.44 |
| MACD | 0.83 | -0.06 |
| Stochastic Oscillator | 88.07 | 45.52 |
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Princeton Bancorp Inc is a full-service financial institution providing personal and business banking services, including checking and savings accounts, as well as a range of lending products such as residential, commercial, construction, and consumer loans, including home equity loans and lines of credit. The Bank operates branches and conducts loan origination activities in areas of the New York City metropolitan area. Its loan portfolio is segmented into commercial real estate (including owner-occupied, non-owner-occupied, and multi-family properties), construction loans (mainly for residential developments), commercial and industrial loans (for business purposes), residential real estate loans (secured by one-to-four family properties), and consumer/HELOC loans.